Hou et al. [32] conducted an open-label, prospective, multicenter, phase III randomized clinical trial investigating the efficacy and safety of gefitinib plus chemotherapy (pemetrexed and platinum) compared to gefitinib alone in untreated patients with EGFR-mutated NSCLC brain metastases. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.